NA-921 (Bionetide™)

NA-921 (Bionetide)™is a small molecule drug that is in Phase 3 clinical trials for the treatment of Rett Syndrome.

How does NA-921 (Bionetide™) work?

NA-921 (Bionetide) can easily cross the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:

* NA-921 exhibits neuroprotection

* NA-921 exhibits neurogenesis, i.e. ability to generate new neurons

* It has great bioavailability in the body

* It is very safe, with no toxicity observed

* It is available in oral formulation


PHASE 2/3 CLINICAL TRIALS of NA-921

Biomed has completed Phase 2/3 clinical trials of NA-921 for the treatment of Rett Syndrome:

To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome
ClinicalTrials.gov ID NCT06849973

A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of NA-921 (Bionetide) for the Treatment of Girls and Women with Rett Syndrome

Primary Objective • To investigate the efficacy and safety of treatment with oral NA-921 (Bionetide) versus placebo in girls and women with Rett syndrome

Key Secondary Objective • To investigate the efficacy of treatment with oral NA-921 (Bionetide) versus placebo on ability to communicate in girls and women with Rett syndrome

The Results of the Phase 2/3 has been announced:

Biomed Industries, Inc. Announces Phase 2/3 Results of NA-921, with Superior Efficacy and Safety for Rett Syndrome


https://www.einpresswire.com/article/790752658/biomed-industries-inc-announces-phase-2-3-results-of-na-921-with-superior-efficacy-and-safety-for-rett-syndrome

PHASE 3 CLINICAL TRIALS OF NA-921

The Phase 3 clinical protocol "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome" has been posted on https://clinicaltrials.gov of the National Institute of Health- United States of America.
ClinicalTrials.gov ID NCT06840496


HOW TO PARTICIPATE IN A PHASE 3 CLINICAL TRIAL OF NA-921

If you wish to participate as a patient or a care-giver of the patient, please complete the online form.



For further information about our products, please contact us. Contact us